HPV18 E1 Protein Plus α-Galactosylceramide Elicit in Mice CD8+ T Cell Cross-Reactivity Against Cells Expressing E1 from Diverse Human Papillomavirus Types-Reference-Cited by-同舟云学术

HPV18 E1 Protein Plus α-Galactosylceramide Elicit in Mice CD8+ T Cell Cross-Reactivity Against Cells Expressing E1 from Diverse Human Papillomavirus Types

Published:2019-07 Issue:6 Volume:32 Page:269-275
ISSN:0882-8245
Container-title:Viral Immunology
language:en
Short-container-title:Viral Immunology

Author:

Amador-Molina Alfredo¹,Amador-Molina Juan C.²,Arciniega Juan L.³,Lizano Marcela¹⁴

Affiliation:

1. Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología, Tlalpan, México.

2. Tecnológico de Monterrey, Departamento de Bioingeniería, Campus Estado de México, Estado de México, México.

3. Biologics Consulting (Affiliate), Department of Pharmaceuticals and Biologics, Alexandria, Virginia.

4. Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad Universitaria, Ciudad de México, México.

Publisher

Mary Ann Liebert Inc

Subject

Virology,Molecular Medicine,Immunology

Link

https://www.liebertpub.com/doi/pdf/10.1089/vim.2019.0020

Reference20 articles.

1. The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2

2. B Subunit of Shiga Toxin-Based Vaccines Synergize with α-Galactosylceramide to Break Tolerance against Self Antigen and Elicit Antiviral Immunity

3. Vaccination with human papillomavirus-18 E1 protein plus α-galactosyl-ceramide induces CD8+ cytotoxic response and impairs the growth of E1-expressing tumors

4. Elevated HPV16 E1 Expression Is Associated with Cervical Cancer Progression

5. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. iNKT cell agonists as vaccine adjuvants to combat infectious diseases;Carbohydrate Research;2022-03